FeesSafety
Pluang+

BDR sues FDA over exclusivity of Phathom's VOQUEZNA, challenging patent extension under GAIN Act.

Market News
23 Oct 2026
Na
View Source
Bearish
BDR sues FDA over exclusivity of Phathom's VOQUEZNA, challenging patent extension under GAIN Act.

BDR Pharmaceuticals has filed a lawsuit against the FDA, disputing the agency's refusal to accept an abbreviated new drug application referencing Phathom Pharmaceuticals' VOQUEZNA. BDR claims the FDA wrongly extended Phathom's exclusivity period under the GAIN Act. Phathom maintains the FDA correctly granted 10 years of exclusivity through 2032 and plans to defend its rights. The outcome could impact VOQUEZNA's market exclusivity and competition timing.

Phathom Pharmaceuticals' litigation update against BDR Pharmaceuticals is presented here with relevant Health-sector market data from Pluang. For readers following Health-sector US stocks, as of Oct 23, 2026 14:31 WIB, out of 150 stocks, 63 rose and 85 fell. Notably, MRVI traded at USD 7.05 with a 6.80% decline and full buy-side order activity, CTXR was priced at USD 0.37 with a 6.42% drop and also 100% buy orders, while XRAY rose 4.41% to USD 9.48 with a typical hold time of 73 days.

More News

Ipsos reports 2.0% organic growth in Q3, upgrades 2026 growth outlook amid AI and digital expansion.

Ipsos reports 2.0% organic growth in Q3, upgrades 2026 growth outlook amid AI and digital expansion.

Ipsos achieved 2.0% organic revenue growth in Q3 2026, up from 0.8% in H1, driven by strong performances in EMEA, China, and citizen-related activities. The company updated its 2026 organic growth target to 1.2%-1.5%, reflecting improved momentum and...

Company Fundamentals
Bullish
2 hours ago
Ipsos reports 2.0% organic growth in Q3 2026, driven by EMEA, China, and Citizens segment.

Ipsos reports 2.0% organic growth in Q3 2026, driven by EMEA, China, and Citizens segment.

Ipsos posted €636.2 million revenue in Q3 2026 with 2.0% organic growth, up from 0.8% in H1, led by strong performances in EMEA, China, and its Citizens business. The company updated its full-year organic growth outlook to 1.2%-1.5%, citing ongoing g...

Company Fundamentals
Bullish
2 hours ago
Signify posts Q3 profit growth despite sales dip, confirms full-year margin outlook

Signify posts Q3 profit growth despite sales dip, confirms full-year margin outlook

Signify reported third-quarter 2026 results with sales of EUR 1,367 million, a slight decline in comparable sales by 3.4%, but improved adjusted EBITA of EUR 145 million and a margin increase to 10.6%. Net income rose to EUR 88 million and free cash ...

Company Fundamentals
Bullish
3 hours ago
Decipher test predicts which high-risk prostate cancer patients benefit from adding abiraterone to treatment.

Decipher test predicts which high-risk prostate cancer patients benefit from adding abiraterone to treatment.

Veracyte's Decipher Prostate Genomic Classifier can predict which men with very high-risk nonmetastatic prostate cancer will benefit from adding abiraterone to androgen deprivation therapy (ADT). This finding, from a Phase III STAMPEDE trial analysis...

Market News
Bullish
4 hours ago
Jupiter Mobile adds Revolut Pay for crypto purchases on Solana-based platform

Jupiter Mobile adds Revolut Pay for crypto purchases on Solana-based platform

Jupiter Mobile users can now use Revolut Pay to buy cryptocurrencies, integrating the popular payment service with the Solana-based trading platform. JupiterExchange operates exclusively on Solana, aggregating orders across multiple liquidity sources...

Protocol Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App